Oncopeptides AB (ONCO) AI Stock Analysis

• Market Cap: kr1.36B
• Dividend Yield: N/A
• Average Volume (3M): 5.74M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: 138.11%
• EPS Growth: 31.65%
• Country: SE
• Employees: 80
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 258,211,430
• 10 Day Avg. Volume: 4,871,248
• 30 Day Avg. Volume: 5,741,998
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr5.00
• Price Target Upside: -8.76% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: kr5.00 ▼(-8.76% Downside)

Oncopeptides AB's overall stock score is primarily influenced by its challenging financial performance, characterized by persistent losses and high leverage. While technical analysis shows some positive momentum, the negative valuation metrics due to ongoing losses weigh heavily on the score.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong market demand for Oncopeptides' products, enhancing its competitive position in the biotech sector.

Cash Position

A strong cash position provides Oncopeptides with the flexibility to manage short-term liabilities and invest in strategic initiatives.

Product Approval

Approval of melflufen in certain markets supports revenue generation and validates Oncopeptides' innovative approach in treating hematological cancers.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk, potentially affecting Oncopeptides' ability to invest in growth opportunities.

Operational Inefficiencies

Operational inefficiencies can erode profitability and hinder Oncopeptides' ability to achieve sustainable growth and improve margins.

Negative Cash Flow

Negative cash flow indicates challenges in generating sufficient cash from operations, which could impact long-term financial stability and growth.

Oncopeptides AB Business Overview & Revenue Model

Company Description

Oncopeptides AB is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of hematological cancers, particularly multiple myeloma. The company operates in the pharmaceutical sector and is dedicated to addressing unmet medical needs through its proprietary drug candidates, most notably melflufen, a peptide-drug conjugate designed to improve patient outcomes in difficult-to-treat malignancies.

How the Company Makes Money

Oncopeptides AB generates revenue primarily through the sales of its therapeutic products, particularly melflufen, which has been approved for use in certain markets. The company may also derive income from partnerships and collaborations with other pharmaceutical companies, where they can receive upfront payments, milestone payments, and royalties based on sales of co-developed products. Additionally, Oncopeptides may benefit from research grants or funding aimed at supporting the development of its drug candidates, which contributes to its overall revenue model.

Oncopeptides AB Financial Statement Overview

Summary

Oncopeptides AB is facing financial challenges with persistent losses, high leverage, and cash flow shortfalls. Despite a strong cash position, the company struggles with operational inefficiencies and high operating costs relative to revenue.

Income Statement

Oncopeptides AB has shown inconsistent revenue trends with significant fluctuations over the years. The company has consistently reported negative net income, indicating ongoing losses. Additionally, the high negative EBIT margin reflects operational inefficiencies or high operating costs relative to revenue.

Balance Sheet

The company's balance sheet shows a high level of liabilities compared to its equity, indicating a high debt-to-equity ratio. However, the company maintains a relatively strong cash position, which could help manage short-term liabilities. The equity ratio has deteriorated over time, suggesting decreasing asset financing through equity.

Cash Flow

Oncopeptides AB has consistently reported negative operating and free cash flows, highlighting cash burn issues. Despite this, the company has managed to secure financing to support operations. The free cash flow to net income ratio is negative, emphasizing the challenge in generating cash from its core operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	39.84M	31.65M	35.22M	8.36M	118.30M	0.00
Gross Profit	37.55M	28.98M	36.30M	8.35M	65.17M	-14.40M
EBITDA	-277.67M	-283.50M	-231.62M	-319.62M	-1.40B	-1.58B
Net Income	-277.57M	-284.61M	-249.11M	-337.95M	-1.43B	-1.59B
Balance Sheet
Total Assets	173.41M	244.19M	238.38M	385.32M	439.38M	946.76M
Cash, Cash Equivalents and Short-Term Investments	107.22M	178.54M	173.44M	344.51M	362.19M	840.25M
Total Debt	118.39M	141.72M	126.16M	9.54M	14.19M	19.36M
Total Liabilities	179.25M	189.91M	181.60M	91.03M	228.51M	369.86M
Stockholders Equity	-5.84M	54.28M	56.78M	294.29M	210.87M	576.90M
Cash Flow
Free Cash Flow	-261.52M	-260.57M	-279.61M	-423.02M	-1.52B	-1.31B
Operating Cash Flow	-261.52M	-260.57M	-279.49M	-420.51M	-1.52B	-1.30B
Investing Cash Flow	496.00K	496.00K	-116.00K	-2.51M	-339.00K	-20.13M
Financing Cash Flow	263.78M	263.81M	106.89M	392.40M	1.03B	1.32B

Oncopeptides AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCO, the sentiment is Positive. The current price of 5.48 is above the 20-day moving average (MA) of 4.70, above the 50-day MA of 4.22, and above the 200-day MA of 2.20, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 59.79 is Neutral, neither overbought nor oversold. The STOCH value of 36.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ONCO.

Oncopeptides AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONCO	54 Neutral	kr1.36B	―		―	138.11%	31.65%
Sector *	51 Neutral	$7.90B	-0.36	-43.38%	2.23%	22.34%	-2.15%
7XB	―	€62.42M	5.60	-26.83%	―	―	―
7ZA	―	€40.91M	―	-133.47%	―	―	―
6XP	―	€169.25M	―	-41.54%	―	―	―
BTPC	―	€20.68M	―	-402.04%	―	―	―
7V3	―	€58.65M	―	-275.87%	―	―	―

Oncopeptides AB Corporate Events

Oncopeptides Partners with SD Pharma to Expand Pepaxti Reach in Spain

Oncopeptides AB has announced a strategic partnership with SD Pharma to expand the reach of its flagship drug, Pepaxti, in Spain. This collaboration aims to enhance Oncopeptides’ commercial presence in Spanish hospitals, leveraging SD Pharma’s expertise in oncology and hematology. The partnership is expected to significantly advance Oncopeptides’ goal of addressing unmet medical needs in the cancer treatment landscape, with activities commencing in Q3 2025 on a success-based model.

Oncopeptides’ Real-World Data Accepted at IMS Annual Meeting

Oncopeptides AB announced the acceptance of two real-world evidence posters for presentation at the International Myeloma Society Annual Meeting. These posters, based on data from Spain and Italy, highlight the clinical use of Pepaxti in treating relapsed or refractory multiple myeloma. The acceptance underscores the importance of real-world data in guiding treatment decisions and building physician confidence in newer therapies. This development is significant for Oncopeptides as it enhances the company’s visibility and credibility in the European market, potentially influencing market access and physician adoption of Pepaxti.

Oncopeptides Reports Strong Q2 2025 Sales Growth

Oncopeptides AB reported higher-than-expected net sales for Q2 2025, with a 45% increase from Q1 and 135% from Q2 2024, driven by strong organic growth in Germany and rapid market access in Spain and Italy. This marks the third consecutive quarter of over 30% sales growth, positioning the company towards profitability by 2026, reflecting robust demand for its cancer treatment, Pepaxti.

Oncopeptides’ Pepaxti Gains Inclusion in European Multiple Myeloma Treatment Guidelines

Oncopeptides AB announced that its drug Pepaxti has been included in the European guidelines for treating relapsed, refractory multiple myeloma, marking a significant recognition of its clinical value. This inclusion is expected to enhance Pepaxti’s awareness and usage across Europe, providing a crucial treatment option for patients with limited alternatives, and reflects the growing trust in its efficacy.

Oncopeptides AB Annual General Meeting: Key Resolutions and Shareholder Program

Oncopeptides AB held its Annual General Meeting where key resolutions were passed, including the adoption of the annual report and the re-election of board members. A new long-term shareholder program was introduced, offering Restricted Share Units to board members, enhancing their stake in the company. The meeting also authorized the Board to issue new shares, warrants, and convertibles, aiming to increase financial flexibility and support potential acquisitions or project development. These decisions are poised to impact Oncopeptides’ operational strategy and shareholder engagement, potentially strengthening its market position.

Oncopeptides Initiates Real-World Study of Pepaxti in Spain

Oncopeptides AB has launched a new real-world evidence study in Spain to evaluate the use of its drug Pepaxti in routine clinical settings for patients with relapsed, refractory multiple myeloma. This study, named LAGOON, marks the first of its kind for Pepaxti in Spain and aims to collect data on the drug’s effectiveness and safety, supporting clinical decision-making and market development. The study’s findings will contribute to Oncopeptides’ efforts to provide relevant data to healthcare providers, payers, and regulators across Europe.

Oncopeptides AB Reports Strong Q1 2025 Growth and Strategic Advances

Oncopeptides AB reported a significant 161% increase in net sales in Q1 2025 compared to the previous year, driven by its expanded commercial footprint in Europe and strategic initiatives. The company secured its first orders in Italy following a positive reimbursement decision and is progressing with partnership negotiations in Japan. Additionally, the FDA lifted the clinical hold on its next-generation drug OPD5, opening new opportunities for market expansion in the U.S. These developments underscore Oncopeptides’ commitment to enhancing its market position and advancing its innovative pipeline.

Oncopeptides AB to Release Q1 2025 Financial Report

Oncopeptides AB announced the upcoming release of its Q1 2025 financial report, scheduled for May 15, 2025. The company will host a webcast and Q&A session for investors, analysts, and media, led by CEO Sofia Heigis and CFO Henrik Bergentoft. This event provides stakeholders an opportunity to gain insights into the company’s financial performance and strategic direction.